TrippBio, Inc.
TrippBio is a pioneering biotech company dedicated to discovering, developing, and commercializing new antiviral treatments, with a focus on viral diseases such as COVID-19, influenza, and RSV. The company aims to bring life-saving, effective, and safe treatments to patients worldwide by leveraging scientific research and innovative drug development.
Industries
Nr. of Employees
small (1-50)
TrippBio, Inc.
10151 Deerwood Park Blvd, Building 200, Suite 250, Jacksonville, FL 32256
Products
Clinical-stage repurposed probenecid-based antiviral (oral suspension development)
A clinical-stage repurposed small-molecule antiviral program based on probenecid chemistry being developed for treatment of respiratory viruses (SARS-CoV-2, influenza, RSV). Program includes preclinical in vitro/in vivo efficacy, Phase 2 clinical data showing reduced viral load and faster symptom resolution, and ongoing formulation work to support broader clinical development.
Clinical-stage repurposed probenecid-based antiviral (oral suspension development)
A clinical-stage repurposed small-molecule antiviral program based on probenecid chemistry being developed for treatment of respiratory viruses (SARS-CoV-2, influenza, RSV). Program includes preclinical in vitro/in vivo efficacy, Phase 2 clinical data showing reduced viral load and faster symptom resolution, and ongoing formulation work to support broader clinical development.
Services
End-to-end clinical development activities for repurposed small-molecule antivirals, including protocol design, randomized dose-ranging trials, safety monitoring, and regulatory interactions to support INDs and later-stage studies.
In vitro potency testing, mechanism-of-action studies, and in vivo efficacy experiments in infection models to support go/no-go decisions and IND-enabling datasets.
Development of oral suspension formulations and soluble analogs/prodrugs to enable flexible dosing across patient populations and indications.
End-to-end clinical development activities for repurposed small-molecule antivirals, including protocol design, randomized dose-ranging trials, safety monitoring, and regulatory interactions to support INDs and later-stage studies.
In vitro potency testing, mechanism-of-action studies, and in vivo efficacy experiments in infection models to support go/no-go decisions and IND-enabling datasets.
Development of oral suspension formulations and soluble analogs/prodrugs to enable flexible dosing across patient populations and indications.
Expertise Areas
- Clinical trial management (Phase 2 randomized studies)
- Antiviral drug repurposing and translational development
- Preclinical virology and animal model efficacy testing
- Host-targeted mechanism research
Key Technologies
- Host-targeting small-molecule antivirals
- Probenecid-based therapeutic chemistry
- Oral suspension formulation
- In vitro cell-based antiviral assays (Vero E6, MDCK, HEp-2, NHBE)
News & Updates
TrippBio showcased data demonstrating 100% protection against lethal H5N1 infection in mice, and discussed the antiviral and anti-inflammatory potential of PanCytoVir™ for COVID-19, influenza, and RSV.
TrippBio Publishes Data Comparing the invitro and in vivo Activity of PanCytoVir™ versus Oseltamivir
The data shows PanCytoVir™ demonstrates greater potency against strains of influenza A and B, including oseltamivir-resistant strains, both in vitro and in vivo.
The study showed PanCytoVir™ significantly shortened viral clearance time and increased symptom resolution in COVID-19 patients.
The last patient was enrolled in the Phase 2 study, which aims to evaluate the efficacy of PanCytoVir™ in COVID-19.
Research led by Ralph Tripp suggests an anti-inflammatory drug used for gout could improve COVID-19 outcomes.
The patent broadens the scope of PanCytoVir™ and related analogs for treating various viruses including SARS-CoV-2, influenza, RSV, measles, mumps, Dengue, and Zika.
TrippBio showcased data demonstrating 100% protection against lethal H5N1 infection in mice, and discussed the antiviral and anti-inflammatory potential of PanCytoVir™ for COVID-19, influenza, and RSV.
TrippBio Publishes Data Comparing the invitro and in vivo Activity of PanCytoVir™ versus Oseltamivir
The data shows PanCytoVir™ demonstrates greater potency against strains of influenza A and B, including oseltamivir-resistant strains, both in vitro and in vivo.
The study showed PanCytoVir™ significantly shortened viral clearance time and increased symptom resolution in COVID-19 patients.
The last patient was enrolled in the Phase 2 study, which aims to evaluate the efficacy of PanCytoVir™ in COVID-19.
Research led by Ralph Tripp suggests an anti-inflammatory drug used for gout could improve COVID-19 outcomes.
The patent broadens the scope of PanCytoVir™ and related analogs for treating various viruses including SARS-CoV-2, influenza, RSV, measles, mumps, Dengue, and Zika.